During a conversation with Astrazeneca boss Pascal Soriot this year, the French executive remarked that British science and pharmaceuticals did not have to be losers from the UK s new relationship with the EU.
In the same way as Soriot defied the odds in 2014, when he repelled a £69billion bid for the company from Pfizer, he regarded the Brexit rage from the science sector as misplaced.
Sure, it would be a loss that the European Medicines Agency (EMA) would be moving from London to the Hague but it offered a real opportunity for the UK s Medicines and Healthcare products Regulatory Agency (MHRA).